Program: PhD
Track: Clinical Pharmaceutical Sciences
Advisor: Thomas D. Nolin, PharmD, PhD

I am a fourth year graduate student in the PhD program (clinical pharmaceutical scientist track) in the School of Pharmacy at the University of Pittsburgh. In 2015 I joined in the lab of Dr. Thomas Nolin, pursuing my second PhD in the School of Pharmacy. I have been interested in inter- and intra-variability in PK/PD and its impact on dose optimization, efficacy, and toxicity. I am especially intrigued by chronic kidney disease (CKD) research for elucidating the relationship between pathophysiological conditions and drug disposition that may cause great variability in clinical outcome. My current project is use of physiologically based pharmacokinetic modeling to evaluate the effect of renal impairment on multiple non-renal elimination pathways. In June 2018 I will start my FDA ORISE fellowship where I will make progress my dissertation research.

I earned a BS from Kyoto University, Japan, and worked as a clinical research associate and later worked as a project manager in a Japanese pharmaceutical company. In 2004, I came back to academia to the graduate program in Biostatistics at the University of Pittsburgh. My thesis research topic was adaptive two-stage dose-response design for proof of concept in drug development. Upon earning my PhD in Biostatistics at the University of Pittsburgh in 2010, I worked as a Research Associate at the Dana-Farber Cancer Institute (DFCI) with an academic appointment at Harvard School of Public Health until September 2013. I served as a Study Statistician or co-investigator collaborating with principal physician-scientists in translational research in medical imaging and in the breast cancer and GI cancer groups of the Eastern Cooperative Oncology Group (ECOG).